Predictive value of serum HMGB1 and Angptl-2 on coronary artery damage in children with Kawasaki disease

doi:10.11958/20242018

Abstract

Abstract:

Objective To investigate the impact and predictive value of high mobility group protein B1 (HMGB1) and angiopoietin like protein 2 (Angptl-2) on coronary artery damage in children with Kawasaki disease. Methods A total of 114 children with Kawasaki disease were selected and divided into the normal coronary artery group (85 cases) and the coronary artery lesion group (29 cases) according to the presence or absence of coronary artery lesions. The general clinical data of the two groups were compared. Enzyme linked immunosorbent assay was applied to detect serum levels of HMGB1 and Angptl-2 in children and compared between the two groups. Logistic regression was applied to analyze the influencing factors of coronary artery damage in children with Kawasaki disease. Receiver operating curve (ROC) was applied to analyze the predictive value of serum levels of HMGB1 and Angptl-2 for coronary artery damage in children with Kawasaki disease. Results The serum levels of HMGB1 and Angptl-2 were significantly higher in acute stage than those in remission stage (P<0.05). Before treatment, the duration of fever, white blood cell count, erythrocyte sedimentation rate, procalcitonin and serum HMGB1 and Angptl-2 levels were significantly higher in the coronary artery lesion group than those in the normal coronary artery group (P<0.05). Logistic regression analysis showed that the duration of fever, white blood cell count, erythrocyte sedimentation rate, procalcitonin, HMGB1 and Angptl-2 levels before treatment were all independent risk factors for coronary artery damage in children with Kawasaki disease (P<0.05). The area under the curve (AUC) of serum HMGB1 and Angptl-2 for diagnosing coronary artery damage in children with Kawasaki disease was 0.907 (95%CI: 0.838-0.953) and 0.857 (95%CI:0.780-0.916), respectively, with cut-off value of 59.62 μg/L and 10.35 μg/L, respectively. The AUC, sensitivity and specificity of the combined diagnosis of coronary artery damage in children with Kawasaki disease were 0.958 (95%CI: 0.903-0.987), 93.10% and 90.59%, respectively, which were better than their individual diagnose. Conclusion The serum levels of HMGB1 and Angptl-2 are obviously elevated in children with Kawasaki disease complicated by coronary artery damage, and the combined detection of HMGB1 and Angptl-2 levels in serum can provide a good prediction for coronary artery damage in children with Kawasaki disease.

Key words: mucocutaneous lymph node syndrome, coronary artery damage, high mobility group protein B1, angiopoietin like protein 2

CLC Number:

R725.4

Figures/Tables 6

References 20

[1]	KUO H C. Diagnosis,progress,and treatment update of Kawasaki disease[J]. Int J Mol Sci, 2023, 24(18):13948. doi:10.3390/ijms241813948.
[2]	DAY-LEWIS M, SON M B F, LO M S. Kawasaki disease:contemporary perspectives[J]. Lancet Child Adolesc Health, 2024, 8(10):781-792. doi:10.1016/S2352-4642(24)00169-X.
[3]	HU J, REN W. Analysis of the risk factors in prognosis of Kawasaki disease with coronary artery lesions[J]. Front Pediatr, 2021, 9:798148. doi:10.3389/fped.2021.798148.
[4]	LIU J, YUE Q, QIN S, et al. Risk factors and coronary artery outcomes of coronary artery aneurysms differing in size and emergence time in children with Kawasaki disease[J]. Front Cardiovasc Med, 2022,9:969495. doi:10.3389/fcvm.2022.969495.
[5]	ZHANG J, ZHUGE Y, RONG X, et al. Protective roles of xijiao dihuang tang on coronary artery injury in Kawasaki disease[J]. Cardiovasc Drugs Ther, 2023, 37(2):257-270. doi:10.1007/s10557-021-07277-w.
[6]	TANG D, KANG R, ZEH H J, et al. The multifunctional protein HMGB1:50 years of discovery[J]. Nat Rev Immunol, 2023, 23(12):824-841. doi:10.1007/s10557-021-07277-w.
[7]	左广锋, 谢浩, 任晓敏, 等. 血管生成素样蛋白-2在急性冠脉综合征患者中的表达及其临床意义[J]. 国际心血管病杂志, 2022, 49(1):48-52.
	ZUO G F, XIE H, REN X M, et al. Expression of Angiopoietin-like protein 2 in patients with acute coronary syndrome and its clinical significance[J]. Int J Cardiol, 2022, 49(1):48-52. doi:10.3969/j.issn.1673-6583.2022.01.013.
[8]	黄玉娟, 李夙凌, 田园, 等. 中国儿童川崎病诊疗循证指南(2023年)[J]. 中国当代儿科杂志, 2023, 25(12):1198-1210.
	HUANG Y J, LI S L, TIAN Y, et al. Evidence-based guidelines for the diagnosis and treatment of Kawasaki disease in Chinese children(2023)[J]. Chinese Journal of Contemporary Pediatrics, 2023, 25(12):1198-1210.
[9]	KOBAYASHI T, FUSE S, SAKAMOTO N, et al. Z score project investigators. a new z score curve of the coronary arterial internal diameter using the lambda-mu-sigma method in a pediatric population[J]. J Am Soc Echocardiogr, 2016, 29(8):794-801.e29. doi:10.1016/j.echo.2016.03.017.
[10]	中华医学会儿科学会分会心血管组, 中华儿科杂志编辑委员会. 川崎病冠状动脉病变的临床处理建议(2020年修订版)[J]. 中华儿科杂志, 2022, 60(1):6-13.
	Chinese Medical Association Pediatrics Branch Cardiovascular Group, Chinese Journal of Pediatrics Editorial Committee. Recommendations for the clinical management of Kawasaki disease coronary artery lesions (Revised Edition 2020)[J]. Chinese Journal of Pediatrics, 2022, 60(1):6-13. doi:10.3760/cma.j.cn112140-20200422-00421.
[11]	杨湖, 雷君, 杨丽, 等. 儿童川崎病并发胸腔积液的临床特点及风险预测模型构建[J]. 天津医药, 2024, 52(10):1089-1094.
	YANG H, LEI J, YANG L, et al. Clinical characteristics and risk prediction model construction of children with Kawasaki disease complicated with pleural effusion[J]. Tianjin Med J, 2024, 52(10):1089-1094. doi:10.11958/20240256.
[12]	SEKI M, MINAMI T. Kawasaki disease:pathology,risks,and management[J]. Vasc Health Risk Manag, 2022, 18:407-416. doi:10.2147/VHRM.S291762.
[13]	SYUKRI A,BUDU, HATTA M, et al. Doxorubicin induced immune abnormalities and inflammatory responses via HMGB1,HIF1-α and VEGF pathway in progressive of cardiovascular damage[J]. Ann Med Surg(Lond), 2022, 76:103501. doi:10.1016/j.amsu.2022.103501.
[14]	苏利叶, 黄兰松, 周尚, 等. 龙血竭总黄酮对大鼠I/R心肌细胞HMGB1/PI3K通路的影响[J]. 右江民族医学院学报, 2024, 46(2):147-152.
	SU L Y, HUANG L S, ZHOU S, et al. Effects of total flavonoids of Dracaena cochinchinensis on HMGB1/PI3K pathway in rat I/R myocardial cells[J]. Journal of Youjiang Medical University for Nationalities, 2024, 46(2): 147-152. doi:10.3969/j.issn.1001-5817.2024.02.001.
[15]	马建宏, 叶瑞兴, 刘长钰, 等. 血清同型半胱氨酸、低氧诱导因子-1α、高迁移率族蛋白B1对急性心肌梗死患者预后的评估价值[J]. 中国临床医生杂志, 2023, 51(12):1445-1448.
	MA J H, YE R X, LIU C Y, et al. The value of serum homocysteine,hypoxia-inducible factor-1α,and high mobility group box protein B1 in evaluating the prognosis of patients with acute myocardial infarction[J]. Chinese Journal of Clinical Physicians, 2023, 51(12):1445-1448. doi:10.3969/j.issn.2095-8552.2023.12.016.
[16]	吴蓉, 邓云霞, 唐湘宇. 冠心病合并2型糖尿病患者血清HMGB1、hs-CRP与冠状动脉病变的相关性研究[J]. 现代医药卫生, 2024, 40(12):2007-2012.
	WU R, DENG Y X, TANG X Y. Correlation between serum HMGB1,hs-CRP and coronary artery lesions in patients with coronary heart disease complicated with type 2 diabetes mellitus[J]. Modern Medicine and Health, 2024, 40(12):2007-2012. doi:10.3969/j.issn.1009-5519.2024.12.006.
[17]	NOVAL RIVAS M, ARDITI M. Kawasaki disease and multisystem inflammatory syndrome in children:common inflammatory pathways of two distinct diseases[J]. Rheum Dis Clin North Am, 2023, 49(3):647-659. doi:10.1016/j.rdc.2023.03.002.
[18]	YU Z, YANG W, HE X, et al. Endothelial cell-derived angiopoietin-like protein 2 supports hematopoietic stem cell activities in bone marrow niches[J]. Blood, 2022, 139(10):1529-1540. doi:10.1182/blood.2021011644.
[19]	CALAND L, LABBÉ P, MAMARBACHI M, et al. Knockdown of angiopoietin-like 2 induces clearance of vascular endothelial senescent cells by apoptosis, promotes endothelial repair and slows atherogenesis in mice[J]. Aging(Albany NY), 2019, 11(11):3832-3850. doi:10.18632/aging.102020.
[20]	廖占玲, 安国印, 吴晶晶, 等. 老年不稳定型心绞痛患者血清Irisin、Angptl 2、CTRP1水平与血脂和冠状动脉病变的相关性分析[J]. 现代生物医学进展, 2022, 22(3):566-569,600.
	LIAO Z L, AN G Y, WU J J, et al. Analysis of the correlation between serum Irisin,Angptl2,CTRP1 levels and blood lipids and coronary artery lesions in elderly patients with unstable angina pectoris[J]. Progress in Modern Biomedicine, 2022, 22(3):566-569,600. doi:10.13241/j.cnki.pmb.2022.03.035.

疾病分期	n	HMGB1	Angptl-2
急性发作期	114	52.42±7.90	9.09±2.31
缓解期	114	28.15±4.61	5.24±1.12
t		64.256^＊＊	33.786^＊＊

疾病分期	n	HMGB1	Angptl-2
急性发作期	114	52.42±7.90	9.09±2.31
缓解期	114	28.15±4.61	5.24±1.12
t		64.256^＊＊	33.786^＊＊

组别		n		性别（男/女）	年龄/ 岁		BMI/ （kg/m²）		治疗前发热时间/d
冠状动脉正常组		85		46/39	3.32±0.48		20.11±2.10		3.80±0.69
冠状动脉损害组		29		21/8	3.15±0.45		20.04±2.06		5.91±1.71
χ²或t				2.987	1.672		0.156		8.604^＊＊
组别	Hb/ （g/L）				Alb/ （g/L）		PLT/ （×10⁹/L）		WBC/ （×10⁹/L）
冠状动脉正常组	104.12±13.79				37.13±5.02		371.59±80.75		11.96±3.02
冠状动脉损害组	103.75±12.88				36.85±4.98		365.42±79.26		13.75±3.27
t	0.127				0.510		0.357		2.699^＊＊
组别			CRP/（mg/L）			ESR/（mm/1 h）		PCT/（μg/L）
冠状动脉正常组			54.45±7.22			49.74±6.24		0.62±0.11
冠状动脉损害组			56.21±7.59			59.28±7.83		1.09±0.25
t			1.119			6.794^＊＊		13.906^＊＊

组别		n		性别（男/女）	年龄/ 岁		BMI/ （kg/m²）		治疗前发热时间/d
冠状动脉正常组		85		46/39	3.32±0.48		20.11±2.10		3.80±0.69
冠状动脉损害组		29		21/8	3.15±0.45		20.04±2.06		5.91±1.71
χ²或t				2.987	1.672		0.156		8.604^＊＊
组别	Hb/ （g/L）				Alb/ （g/L）		PLT/ （×10⁹/L）		WBC/ （×10⁹/L）
冠状动脉正常组	104.12±13.79				37.13±5.02		371.59±80.75		11.96±3.02
冠状动脉损害组	103.75±12.88				36.85±4.98		365.42±79.26		13.75±3.27
t	0.127				0.510		0.357		2.699^＊＊
组别			CRP/（mg/L）			ESR/（mm/1 h）		PCT/（μg/L）
冠状动脉正常组			54.45±7.22			49.74±6.24		0.62±0.11
冠状动脉损害组			56.21±7.59			59.28±7.83		1.09±0.25
t			1.119			6.794^＊＊		13.906^＊＊

组别	n	HMGB1	Angptl-2
冠状动脉正常组	85	49.71±7.09	8.15±1.96
冠状动脉损害组	29	60.38±8.13	11.83±2.59
t		6.738^＊＊	8.015^＊＊